STOCK PURCHASE AGREEMENTStock Purchase Agreement • February 16th, 2021 • Adicet Bio, Inc. • Pharmaceutical preparations
THIS STOCK PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of February 12, 2021 (the “Effective Date”), by and between Adicet Bio, Inc., a Delaware corporation (the “Company”), and the purchasers listed on Schedule A hereto (each a “Purchaser” and, collectively, the “Purchasers”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • February 16th, 2021 • Adicet Bio, Inc. • Pharmaceutical preparations
This Registration Rights Agreement (this “Agreement”) is dated as of February [•], 2021, by and among Adicet Bio, Inc., a Delaware corporation (the “Company”), and the several purchasers signatory hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
9,230,770 Shares of Common Stock ADICET BIO, INC. UNDERWRITING AGREEMENTAgreement • February 16th, 2021 • Adicet Bio, Inc. • Pharmaceutical preparations • New York
Adicet Bio, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 9,230,770 shares (the “Firm Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”). The Company also proposes to issue and sell to the several Underwriters up to an additional 1,344,743 shares (the “Additional Shares”) of Common Stock at the option of the Underwriters as provided in Section 2(c) below. The Firm Shares and any Additional Shares purchased by the Underwriters are referred to herein as the “Shares.” Guggenheim Securities, LLC (“Guggenheim Securities”) is acting as representative (the “Representative”) of the several Underwriters in connection with the offering and sale of the Shares contemplated herein (the “Offering”).
